Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 8, 2015, Pages 337.e1-337.e6

  Rajan, Prabhakar ^a   Frew, John A ^b   Wilson, James M ^b,d   Azzabi, Ashraf S T ^b   McMenemin, Rhona M ^b   Stockley, Jacqueline ^a   Soomro, Naeem A ^b   Durkan, Garrett ^b,e   Pedley, Ian D ^b   Leung, Hing Y ^a,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Androgen deprivation therapy; Docetaxel; Prostate cancer; Prostatic biopsy

Indexed keywords

DOCETAXEL; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; TAXOID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; FATIGUE; FEASIBILITY STUDY; FOLLOW UP; HOT FLUSH; HUMAN; HUMAN TISSUE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TRANSRECTAL ULTRASONOGRAPHY; BIOPSY; CLINICAL TRIAL; MIDDLE AGED; PROSTATIC NEOPLASMS;

AGED; ANDROGEN ANTAGONISTS; BIOPSY; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84937519279     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.05.012     Document Type: Article

References (27)

1. Dowlati A., Haaga J., Remick S.C., et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 2001, 7:2971-2976.
2. Andre F., Mardis E., Salm M., et al. Prioritizing targets for precision cancer medicine. Ann Oncol 2014, 25:2295-2303.
3. Mottet N., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59:572-583.
4. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
5. Omlin A., Pezaro C., Mukherji D., et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 2013, 64:300-306.
6. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
7. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
8. Krishnan A., Wilson J., Leung H.Y. Approaches for developing novel microtubule targeting agents (MTAs) for therapeutic exploitation. Curr Pharm Des 2012, 18:2804-2810.
9. Nehme A., Varadarajan P., Sellakumar G., et al. Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells. Br J Cancer 2001, 84:1571-1576.
10. Sobin L.H., Gospodarowicz M.K., Wittekind C. TNM Classification of Malignant Tumours 2009, Wiley, New York.
11. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58-64.
12. Graham J., Baker M., Macbeth F., et al. Diagnosis and treatment of prostate cancer: summary of NICE guidance. Br Med J 2008, 336:610-612.
13. Pedley I.D., Frew J.A., Wilson J.M., et al. Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: a phase II, open-labeled, randomized study. J Clin Oncol 2009, 29. [Abstract 147].
14. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
15. Gravis G., Fizazi K., Joly F., et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013, 14:149-158.
16. Sweeney C., Chen Y.-H., Carducci M.A., et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol 2014, 32. [Abstract LBA2].
17. Fizazi K., Laplanche A., Lesaunier F., et al. Docetaxel-estramustine in localized high-risk prostate cancer: results of the French Genitourinary Tumor Group GETUG 12 phase III trial. J Clin Oncol 2014, 32. [Abstract 5005].
18. Anastasiadis A., Zapala L., Cordeiro E., et al. Complications of prostate biopsy. Expert Rev Anticancer Ther 2013, 13:829-837.
19. Rajan P., Stockley J., Sudbery I.M., et al. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer 2014, 14:977.
20. Rajan P., Sudbery I.M., Villasevil M.E., et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol 2014, 66:32-39.
21. Pantel K., Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction?. Cancer Res 2013, 73:6384-6388.
22. Bettegowda C., Sausen M., Leary R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6:224ra24.
23. Carreira S., Romanel A., Goodall J., et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014, 6:254ra125.
24. Antonarakis E.S., Lu C., Wang H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014, 371:1028-1038.
25. Alix-Panabieres C., Pantel K. Challenges in circulating tumor cell research. Nat Rev Cancer 2014, 14:623-631.
26. Khurana K.K., Grane R., Borden E.C., et al. Prevalence of circulating tumor cells in localized prostate cancer. Curr Urol 2013, 7:65-69.
27. Loh J., Jovanovic L., Lehman M., et al. Circulating tumor cell detection in high-risk non-metastatic prostate cancer. J Cancer Res Clin Oncol 2014, 140:2157-2162.